Celcuity (CELC) Slides As Fair Value Debate Builds, Is It Still 65% Undervalued?

Celcuity (CELC) drew fresh attention after recent trading left the stock down 30% over the past month and about 38% over the past 3 months, which has sharpened focus on its clinical-stage biotech profile.

Over the past year, momentum in Celcuity has cooled, with the share price retreating sharply in recent weeks and the 1-year total shareholder return down 19.84%, even as the 3-year total shareholder return sits at more than 4x the starting point.

Stress test your thesis on Celcuity by comparing it with a curated 33 high quality undervalued stocks that currently combines compressed share prices with stronger fundamentals.

After a 3 month slide and a 3 year return that is already more than 4x, Celcuity now sits at a crossroads. Has most of the rerating played out, or does the current valuation still leave meaningful upside on the table?

Most Popular Narrative: 65% Undervalued

Against a last close of $56.58, the most widely followed narrative pegs Celcuity’s fair value at about $161.09. This frames today’s pullback against a much higher long term valuation anchor built on gedatolisib’s potential.

Management estimates a US$5b to US$6b addressable market in second line HR positive, HER2 negative advanced breast cancer and has indicated potential peak revenue for gedatolisib of US$2.5b to US$3b in this setting. If partially realized, this would be a key driver of top line growth over time.

See why 5 investors see Celcuity as 65% undervalued.

Result: Fair Value of $161.09 (UNDERVALUED)

Still, the bullish Celcuity narrative hinges on key swing factors, including future FDA decisions on gedatolisib and whether ongoing VIKTORIA-2 data meet current expectations.

Find out about the key risks to this Celcuity narrative.

Next Steps

Mixed feelings after all that Celcuity detail. If you want to move fast and build your own conviction, start with the 3 key rewards and 3 important warning signs.

Looking for more Celcuity-sized ideas?

If Celcuity has sharpened your appetite for opportunity, do not stop here. Use the Simply Wall St screener to pressure test fresh ideas before they move.

• Target potential mispricing by scanning a 33 high quality undervalued stocks that may pair compressed valuations with solid underlying metrics.
• Prioritise resilience by working through a 32 resilient stocks with low risk scores that focuses on businesses with lower overall risk scores.
• Hunt for under-the-radar potential with a 20 high quality undiscovered gems designed to surface quality companies that many investors might be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com